Two Sigma Advisers LP acquired a new position in Immunomedics, Inc. (NASDAQ:IMMU) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 265,710 shares of the biopharmaceutical company’s stock, valued at approximately $9,417,000.
A number of other large investors have also modified their holdings of IMMU. Front Row Advisors LLC bought a new stake in Immunomedics during the second quarter valued at about $35,000. Windsor Creek Advisors LLC bought a new stake in shares of Immunomedics in the first quarter valued at about $40,000. Pathstone Family Office LLC acquired a new position in Immunomedics in the first quarter worth about $40,000. Verus Capital Partners LLC acquired a new position in Immunomedics in the first quarter worth about $54,000. Finally, Emerald Mutual Fund Advisers Trust acquired a new position in Immunomedics in the second quarter worth about $64,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.
Several research firms have recently weighed in on IMMU. Guggenheim lowered shares of Immunomedics from a “buy” rating to a “neutral” rating in a report on Tuesday, September 15th. Cowen reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Immunomedics in a research note on Monday, July 6th. Barclays reaffirmed a “hold” rating and issued a $88.00 price objective on shares of Immunomedics in a research note on Wednesday, September 16th. HC Wainwright cut shares of Immunomedics from a “buy” rating to a “neutral” rating in a research report on Monday, September 14th. Finally, Bank of America lifted their price target on shares of Immunomedics from $45.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Eight analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Immunomedics presently has an average rating of “Hold” and a consensus price target of $46.85.
Immunomedics (NASDAQ:IMMU) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.39). The company had revenue of $20.07 million for the quarter, compared to analyst estimates of $24.81 million. As a group, equities analysts expect that Immunomedics, Inc. will post -1.06 EPS for the current year.
Immunomedics Company Profile
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.
Featured Story: Learning About the VIX – Volatility Index
Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.